Trial · NCT06283303
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
NCT06283303, Phase 1, Unknown, China Medical University, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer. Trials, record NCT06283303. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06283303
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- NCT number
- NCT06283303
- Status
- Unknown
- Phases
- Phase 1
- Enrollment
- 8 participants, estimated
- Lead sponsor
- China Medical University, China
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- T3011 hepatic artery infusion, toripalimab, regorafenib
- First posted
- 2024-02-28
- Last updated
- 2024-02-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Emergent Adverse Event（TEAE） | Complete records until 30 days after the end-of-trial visit (i.e. end of treatment or early termination visit) | An adverse event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. |
| Secondary | Objective response rate (ORR) | Imaging was performed after completion of the introductory period, i.e. at week 4, and tumour assessment was performed every 8 weeks during the subsequent combined treatment period，assessed up to 100 months | Objective response rate (ORR) as assessed by the investigators |
| Secondary | Overall survival (OS) | Every 3 months until consent withdraw, death, withdrawal study, or loss of follow-up, assessed up to 100 months | The time from the start of treatment to death for any cause |
| Secondary | Progression-free survival (PFS) | Every 8 weeks until disease progression, consent withdraw, death or end of study, assessed up to 100 months | The time from the start of treatment to progress diease or death for any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06283303
GET https://conductscience.org/api/trials/v1/NCT06283303/registered